Arrowstreet Capital
SMMT icon

Arrowstreet Capital’s Summit Therapeutics SMMT Stock Holding History

Arrowstreet Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-141,680
Closed -$1.1M – 1858
2024
Q2 		$1.1M Buy
+141,680
New +$765K ﹤0.01% 1197
2021
Q4 		– Sell
-14,410
Closed -$72K – 1695
2021
Q3 		$72K Sell
14,410
-12,790
-47% -$91.8K ﹤0.01% 1546
2021
Q2 		$203K Buy
+27,200
New +$178K ﹤0.01% 1786

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Arrowstreet Capital's SMMT Position: Q3 2024 in Review

Arrowstreet Capital sold out of Summit Therapeutics (SMMT) in Q3 2024, closing a stake of 141,680 shares — an estimated $1.1M sold.

Arrowstreet Capital first reported a position in SMMT in Q2 2021 and held it in 3 quarters. The position peaked at $1.1M in Q2 2024. 166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

  • Arrowstreet Capital reported no remaining Summit Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 141,680 Summit Therapeutics shares in Q3 2024, an estimated $1.1M.
  • Arrowstreet Capital first reported a position in Summit Therapeutics in Q2 2021 and held it in 3 quarters.
  • Arrowstreet Capital's Summit Therapeutics position peaked at $1.1M in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on Arrowstreet Capital's 13F filing for Q3 2024, filed 14 Nov 2024.